BioView and ScreenCell Announce Worldwide Commercial Collaboration Agreement for Circulating Tumor Cell (CTC) Technology
REHOVOT, Israel and PARIS, July 9, 2012 /PRNewswire/ –
BioView Ltd. (TASE: BIOV) and ScreenCell, a privately-held company, today jointly
announced the signing of a commercial collaboration agreement for Bioview’s Automated Cell
Imaging Systems for imaging of CTC’s isolated with ScreenCell’s Cyto Kit (R).
Dr. Alan Schwebel, President and CEO of BioView, views this agreement as a unique
combination of two innovative technologies, one designed by ScreenCell to isolate rare
cells of potentially significant prognostic and predictive value in cancer, and another,
BioView’s scanning platform, which provides automated imaging and analysis solutions for
rare cell and circulating tumor cell detection. “BioView’s unique automated imaging and
analysis solutions for the detection and of rare cells greatly enhance research and
clinical laboratory productivity and assay development process. We are proud to be
ScreenCell’s global partner and look forward to expanding our relationship.”
Bioview’s Imaging Systems are designed to accommodate both the need for CTC
enumeration and retrieval of cellular and marker characteristics of captured cells.
Utilizing field-proven algorithms developed and perfected in collaboration with leading
cancer research centers worldwide, BioView’s scanning platform is the ideal solution for
both clinical and research laboratories wishing to enhance their productivity and assay
ScreenCell offers innovative, single-use devices to isolate by size and characterize a
wide variety of tumor cells, both live and fixed, including mesenchymal cells, cancer stem
cells, microembolii and cancer cells of non-epithelial origin. These cells, which are
considered to be important in metastasis, are often not captured or cannot be sensitively
detected through existing technologies that only target cells expressing EpCam, a
transmembrane glycoprotein on epithelial cells. With the ScreenCell devices, collected
cells are also well preserved morphologically and can be isolated and grown in culture for
drug screening or further genomics analysis.
“Our goal in designing ScreenCell technologies was to create a universal system, not
limited to detection of cells of non-epithelial origin and free of any bias potentially
linked to the use of antibodies for cell capture,” stated David Znaty, Chief Executive
Officer of ScreenCell. “Our objective is to support a breakthrough in personalized
medicine by creating a non-invasive evaluation of specific therapeutic targets and ‘real
time’ monitoring of target evolution which we strongly believe will be facilitated by
combining ScreenCell and BioView technologies.”
About BioView Ltd.
Established in 2000, and led by an expert team of biologists, software engineers and
physicists, BioView develops, manufactures and supplies cell imaging equipment, biological
kits and software to medical institutes and universities. BioView is a publicly traded
company on the Israeli Stock exchange, and currently has strategic collaborations underway
with international scientific leaders and institutions. For more information about the
BioView technology, and press related issues, please contact email@example.com or
visit our website at http://www.bioview.co.il.
ScreenCell was founded with the objective of designing and producing a simple but
revolutionary technique allowing the fast and effective filtering of Rare Circulating
Cells yielding high-quality CTC population amenable to better cellular and molecular
ScreenCell designed a full range of point of care devices for development for use in
in vitro Diagnostics (IVD) assays and platforms.
ScreenCell is dedicated to creating technologies allowing CTCs to become potential end
points in future oncology therapeutic arsenals by filtering out healthy live tumor cells,
- molecular biology - cell culture - enumeration and cytomorphology evaluation
For more information about ScreenCell, please visit http://www.screencell.com.
Contact Information: BioView Dr. Alan Schwebel President and CEO Tel: +972-8-936-6868 firstname.lastname@example.org ScreenCell David Znaty CEO +33(0)1-53-61-91-33 email@example.com
SOURCE BioView Ltd